Combination therapy can delay resistance of lung cancer cells

A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...

Oncology & Cancer

Potential therapeutic target for small cell lung cancer discovered

Northwestern Medicine investigators have discovered that inhibiting a chromatin remodeling complex associated with a particular gene in small-cell lung cancer (SCLC) cells may decrease cancer cell differentiation and tumor ...

page 1 from 40